Pruebas cronometradas en pacientes deambuladores con enfermedades neuromusculares

  • Julieta Mozzoni Hospital de Pediatría Juan P. Garrahan
Palabras clave: enfermedades neuromusculares, desempeño funcional, pruebas cronometradas

Resumen

Las enfermedades neuromusculares se caracterizan por debilidad muscular progresiva, que afecta la deambulación y el desempeño en actividades funcionales como las transferencias, correr, saltar, subir y bajar rampas o escaleras, entre otras.

Para medir objetivamente el compromiso motor de los pacientes deambuladores, entre otras herramientas disponibles, existen las pruebas de tiempo o cronometradas, que valoran la velocidad para realizar determinadas tareas funcionales.

En este trabajo se describen los procedimientos para realizar las cuatro pruebas cronometradas más utilizadas en la evaluación y el seguimiento de los pacientes neuromusculares deambuladores: pararse desde supino, marcha o carrera de 10 metros y subir y bajar 4 escalones.

Descargas

La descarga de datos todavía no está disponible.

Citas

Kennedy R, Carroll K, McGinlye J, Paterson K. Walking and weakness in children: a narrative review of gait and functional ambulation in paediatric neuromuscular disease. J Foot Ankle Res. 2020; 13:10.

Mercuri E, Finkel R, Muntoni F, Wirth B, Montes J, Main M, Mazzone E, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28:103-115.

Birnkrant D, Bushby K, Bann C, Apkon S, Blackwell A, Tomezsko D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251-267.

McDonald C, Henricson E, Abresch T, Florence J, Eagle M, Gappmaier E, et al. The 6-minute walk test and other clinical endpoints in Duchenne Muscular Dystrophy: reliability, concurrente validity and minimal clinically important differences from a multicenter study. Muscle Nerve. 2013;48:357–368.

Chacon Pereira A, Gonçalves Ribeiro M, Prufer de Queiroz Campos Araújo A. Timed motor function tests capacity in healthy children. Arch Dis Child. 2016; 101:147-151.

Hoskens J, Goemans N, Feys H, De Waelec L, Van den Hauwec M, Klingels K. Normative data and percentile curves for the three-minute walk test and timed function tests in healthy Caucasian boys from 2.5 up to 6 years old. Neuromuscul DIsord. 2019;29:585-600.

Pane M, Mazzone E, Sivo S, Sormani M, Messina S, Damico A, et al. Long term natural history data in ambulant boys with Duchenne Muscular Dystrophy: 36-month changes. PLoS One. 2014;9(10):e108205.

Duong T, Canbek J, Birkmeierc M, Nelson L, Sienere C, Fernandez-Fernandez A, et al. The Minimal Clinical Important Difference (MCID) in annual rate of change of timed function tests in boys with DMD. J Neuromuscul Dis. 2021;8:939-948.

Jimenez-Moreno A, Nikolenko N, Kierkegaard M, Blain A, Newman J, Massey C, et al. Analysis of the functional capacity outcome measures for myotonic dystrophy. Ann Clin Transl Neurol. 2019;6(8):1487-1497.

Meilleur K, Jain M, Hynan L, Shieh C, Kim E, Waite M, et al. Results of a two-year pilot study of clinical outcome measures in Collagen VI-related Myopathy and LAMA2-related Muscular Dystrophy. Neuromuscul Disord. 2015;25(1):43-54.

Arora H, Willcocks R, Lott D, Harrington A, Senesac C, Zilke K, et al. Longitudinal timed function tests in Duchenne muscular dystrophy: Imaging DMD cohort natural history. Muscle Nerve. 2018;58(5):631-638.

Quigg K, Berggren K, McIntyre M, Bates K, Salmin F, Casiraghi J, et al. 12-Month progression of motor and functional outcomes in Congenital Myotonic Dystrophy. Muscle Nerve. 2021;63(3):384-391.

Moore U, Jacobs M, James M, Mayhew A, Fernandez Torron R, Feng, J, et al. Assessment of disease progression in dysferlinopathy A 1-year cohort study. Neurology. 2019;92:e461-e474.

Goemans N, Wong B, Van den Hauwe M, Signorovitch J, Sajeev G, Cox D, et al. Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration. PLoS ONE.2020;5(6):e0232870.

Krosschell K, Townsend W, Kiefer M, Simeone S, Zumpf K, Welty L, et al. Natural history of 10-meter walk/run test performance in spinal muscular atrophy: A longitudinal análisis. Neuromuscul Disord. 2022;32(2):125-134.

Mercuri E, Muntoni F, Nascimento Osorio A, Tulinius M, Buccella F, Morgenroth L, et al. Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study. J Comp Eff Res. 2020;9(5):341–360.

Nagy S, Hafner P, Schmidt S, Rubino-Nacht D, Schädelin S, Bieri O, et al. Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial. Trials. 2019;20:637.

Mah J, Clemens P, Gulieri M, Smith E, Finkel R, Tulinius M, et al. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy A 30-Month Nonrandomized Controlled Open-Label Extension Trial. JAMA Network Open. 2022;5(1):e2144178.

Finkel R, McDonald C, Sweeney L, Finanger E, Knierbein E, Wagner K, et al. A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD Trial. J Neuromuscul Dis. 2021;8(5):769-784.

Miller N, Alfano L, Iammarino M, Connolly A, Moore-Clingenpeel M, Powers B, et al. Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests. Pediatric Neurology. 2020;113:15-20.

Duong T, Canbek J, Fernandez-Fernandez A, Henricson E, Birkmeier M, Siener C, et al. Knee strenght and ankle range of motion impacts on time function test in Duchenne Muscular Dystrophy; in the era of glucocorticoids. J Neuromuscul Dis. 2022;9(1):147-159.

Bello L, Morgenroth L, Gordish Dressman, H, Hoffman E, McDonald C, Cirak S.DMD genotypes and los of ambulation in the CINRG Duchenne natural history study. Neuromuscul Dis.2016;26(2):S119.

Publicado
2022-10-25
Cómo citar
Mozzoni, J. (2022). Pruebas cronometradas en pacientes deambuladores con enfermedades neuromusculares. Argentinian Journal of Respiratory & Physical Therapy, 4(3). https://doi.org/10.58172/ajrpt.v4i3.231